AKD has advised ISA Pharmaceuticals B.V. on the investment of Regeneron Pharmaceuticals, Inc. in ISA Pharmaceuticals.

ISA Pharmaceuticals is an immunotherapy company developing treatments for various cancers and infectious diseases. ISA Pharmaceuticals has a strategic collaboration with Regeneron for its lead asset, ISA101b, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer.

ISA Pharmaceuticals plans to initiate a new oropharyngeal cancer trial, a type of head- and neck cancer, under its strategic immune-oncology collaboration with Regeneron. In addition, Regeneron will increase its equity stake in ISA Pharmaceuticals. According to the managing director of ISA Pharmaceuticals, the revised collaboration agreement between ISA Pharmaceuticals and Regeneron will accelerate the development and commercialization of ISA Pharmaceutical's lead asset, ISA101b, to treat two important cancers with high unmet medical needs.

The AKD team consisted of Nathalie van Woerkom, Rosanne Vlasveld and Rianne Wessels. They worked closely with Angelique Martens of the notarial department.

Click press release for ISA Pharmaceutical's official press release.